Correction to: PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
| Autor: | Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., Denkert, C., Schem, C., Sotiriou, C., Loi, S., Untch, M., Conte, P., Bernards, R., Piccart, M., von Minckwitz, G., Baselga, J. |
|---|---|
| Zdroj: | In Annals of Oncology October 2018 29(10):2151-2151 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|